A CRISPR-Cas9 screen for novel proteins required for induction of CYP1A1 by AHR

CRISPR-Cas9 筛选 AHR 诱导 CYP1A1 所需的新型蛋白质

基本信息

项目摘要

 DESCRIPTION (provided by applicant): The environmental pollutant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) has a large number of toxic effects, including carcinogenicity. All the toxic effects of TCDD and of related polychlorinated compounds are mediated by the Aryl Hydrocarbon Receptor (AHR) and depend upon transcriptional activation by the AHR of not yet fully identified downstream genes. AHR also mediates carcinogenesis by polycyclic aromatic hydrocarbons, (e.g. benzo[a]pyrene) which are important carcinogens in tobacco smoke and smog. CYP1A1, CYP1A2 and CYP1B1 are massively induced in many tissues and are likely responsible for mediating the carcinogenic effects of PAHs, via metabolizing them to electrophilic derivatives. After binding agonist, the AHR translocates to the nucleus and forms a dimer with the aryl hydrocarbon nuclear translocator (ARNT) protein, which then binds to the enhancer regions of responsive genes, thereby leading to their transcriptional activation. In the current proposal we will seek to identify novel gene products that play roles in the induction of gene transcription by AHR, by screening a CRISPR-Cas9 library. The CRISPR-Cas9 system can induce DNA double strand breaks at specific genomic loci through synthetic 20 nucleotide sequences within guide RNAs (gRNAs), which when targeted to coding regions of genes can generation of deletions or insertions, resulting in frameshift mutations which lead to loss of function at both alleles in a diploid cell. There are two specific aims. In Specific Aim 1, genes required for CYP1A1 induction will be identified by using the GeCKOv2 library, which targets 20,611 mouse genes (and thus nearly all protein coding genes) and also 1,178 microRNAs. The library is contained in a single high titer lentiviral vector (lentiCRISPRv2), which will be transduced into the mouse hepatoma cell line, Hepa-1. The transduced cells will be selected for 10 days in benzo[a]pyrene. (Benzo[a]pyrene-resistant clones exhibit loss of AHR-dependent induction of CYP1A1). PCR amplification of the integrated gRNAs and their sequencing will then be performed. Those genes represented by more than one gRNA, and/or identified in more than one transduced culture, and/or represented at high frequency, are likely to represent true positives. Specific Aim 2 will validate hits from the screen. Two gRNAs for each gene of interest will be inserted into lentiCRISPRv2 to determine if they confer benzo[a]pyrene resistance, reduce TCDD induction of CYP1A1, and reduce AHR and ARNT expression upon transduction into Hepa-1 cells. The corresponding endogenous genes will be sequenced in certain transductants to see if they contain deletions or insertions. Characterization of confirmed hits will be pursued in a future R01 application. Such hits may include gene products that affect AHR or ARNT expression or function, and/or that are required for transcriptional activation of CYP1A1. The current proposal therefore lays the foundations for a comprehensive analysis of the mechanism of AHR-dependent induction of gene transcription, and may lead to strategies for reducing the harmful effects of ligands of the AHR.
 描述(由申请人提供):环境污染物2,3,7,8-四氯二苯并-对二恶英(TCDD)具有大量毒性作用,包括致癌性。TCDD和相关多氯化合物的所有毒性作用都是介导的。芳基烃受体 (AHR) 的作用,并依赖于 AHR 尚未完全鉴定的下游基因的转录激活,AHR 还通过多环介导致癌作用。芳香烃(例如苯并[a]芘)是烟草烟雾和烟雾中的重要致癌物,在许多组织中大量诱导产生,并可能通过将多环芳烃代谢为亲电子衍生物而介导多环芳烃的致癌作用。结合激动剂后,AHR 易位至细胞核并与芳烃核易位蛋白形成二聚体(ARNT) 蛋白,然后与响应基因的增强子区域结合,从而导致其转录激活。在当前的提案中,我们将寻求鉴定在其中发挥作用的新基因产物。 通过筛选 CRISPR-Cas9 文库,AHR 诱导基因转录 CRISPR-Cas9 系统可以通过引导 RNA (gRNA) 内合成的 20 个核苷酸序列诱导特定基因组位点的 DNA 双链断裂,当靶向引导 RNA 的编码区时。基因可以产生缺失或插入,从而导致移码突变,从而导致二倍体细胞中两个等位基因的功能丧失。在具体目标1中,有两个具体目标。 CYP1A1 诱导所需的基因将通过使用 GeCKOv2 文库进行鉴定,该文库针对 20,611 个小鼠基因(以及几乎所有蛋白质编码基因)和 1,178 个 microRNA。该文库包含在单个高效价慢病毒载体 (lentiCRISPRv2) 中。 将转导至小鼠肝癌细胞系Hepa-1中。转导的细胞将在苯并[a]芘中选择10天(苯并[a]芘抗性克隆表现出AHR依赖性CYP1A1诱导的丧失)。然后将对整合的 gRNA 进行 PCR 扩增及其测序,这些基因由一种以上 gRNA 代表,和/或在一种以上转导培养物中鉴定,和/或以高浓度代表。具体目标 2 将验证每个感兴趣基因的两个 gRNA 将被插入 lentiCRISPRv2 中,以确定它们是否具有苯并[a]芘抗性、减少 CYP1A1 的 TCDD 诱导,以及转导至 Hepa-1 细胞后减少 AHR 和 ARNT 表达。将对某些转导子中的相应内源基因进行测序,以了解它们是否包含缺失或插入。此类命中可能包括影响 AHR 或 ARNT 表达或功能的基因产物,和/或 CYP1A1 转录激活所需的基因产物,因此,当前的提议为全面分析 AHR 机制奠定了基础。基因转录的依赖性诱导,并可能导致减少 AHR 配体有害影响的策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

OLIVER nmn HANKINSON其他文献

OLIVER nmn HANKINSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('OLIVER nmn HANKINSON', 18)}}的其他基金

A CRISPR-Cas9 screen for novel proteins required for induction of CYP1A1 by AHR
CRISPR-Cas9 筛选 AHR 诱导 CYP1A1 所需的新型蛋白质
  • 批准号:
    9276681
  • 财政年份:
    2016
  • 资助金额:
    $ 19.25万
  • 项目类别:
Function and Regulation of Human Cytochrome P4502S1
人细胞色素P4502S1的功能和调控
  • 批准号:
    7811735
  • 财政年份:
    2009
  • 资助金额:
    $ 19.25万
  • 项目类别:
Training in Molecular Toxicology
分子毒理学培训
  • 批准号:
    9100716
  • 财政年份:
    2008
  • 资助金额:
    $ 19.25万
  • 项目类别:
Training in Molecular Toxicology
分子毒理学培训
  • 批准号:
    8101169
  • 财政年份:
    2008
  • 资助金额:
    $ 19.25万
  • 项目类别:
Training in Molecular Toxicology
分子毒理学培训
  • 批准号:
    8294951
  • 财政年份:
    2008
  • 资助金额:
    $ 19.25万
  • 项目类别:
Training in Molecular Toxicology
分子毒理学培训
  • 批准号:
    7647327
  • 财政年份:
    2008
  • 资助金额:
    $ 19.25万
  • 项目类别:
Training in Molecular Toxicology
分子毒理学培训
  • 批准号:
    8667052
  • 财政年份:
    2008
  • 资助金额:
    $ 19.25万
  • 项目类别:
Training in Molecular Toxicology
分子毒理学培训
  • 批准号:
    7434123
  • 财政年份:
    2008
  • 资助金额:
    $ 19.25万
  • 项目类别:
Training in Molecular Toxicology
分子毒理学培训
  • 批准号:
    8693345
  • 财政年份:
    2008
  • 资助金额:
    $ 19.25万
  • 项目类别:
Training in Molecular Toxicology
分子毒理学培训
  • 批准号:
    7885657
  • 财政年份:
    2008
  • 资助金额:
    $ 19.25万
  • 项目类别:

相似国自然基金

儿童药品不良反应主动监测中时序处理策略的方法学研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
基于真实世界医疗大数据的中西药联用严重不良反应监测与评价关键方法研究
  • 批准号:
    82274368
  • 批准年份:
    2022
  • 资助金额:
    52 万元
  • 项目类别:
    面上项目
基于隐狄利克雷分配模型的心血管系统药物不良反应主动监测研究
  • 批准号:
    82273739
  • 批准年份:
    2022
  • 资助金额:
    52 万元
  • 项目类别:
    面上项目
基于真实世界数据的创新药品上市后严重罕见不良反应评价关键方法研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
OR10G7错义突变激活NLRP3炎症小体致伊马替尼严重皮肤不良反应的机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    52 万元
  • 项目类别:
    面上项目

相似海外基金

A CRISPR-Cas9 screen for novel proteins required for induction of CYP1A1 by AHR
CRISPR-Cas9 筛选 AHR 诱导 CYP1A1 所需的新型蛋白质
  • 批准号:
    9276681
  • 财政年份:
    2016
  • 资助金额:
    $ 19.25万
  • 项目类别:
Investigating aryl hydrocarbon receptor-cofactor interactions that mediate toxicity
研究介导毒性的芳烃受体-辅因子相互作用
  • 批准号:
    9024795
  • 财政年份:
    2016
  • 资助金额:
    $ 19.25万
  • 项目类别:
Subproject Investigator: Celine A. Beamer
子项目研究员:Celine A. Beamer
  • 批准号:
    9322425
  • 财政年份:
  • 资助金额:
    $ 19.25万
  • 项目类别:
Subproject Investigator: Celine A. Beamer
子项目研究员:Celine A. Beamer
  • 批准号:
    9534682
  • 财政年份:
  • 资助金额:
    $ 19.25万
  • 项目类别:
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)
淋巴管平滑肌瘤病 (LAM) 发病机制的特征
  • 批准号:
    7734978
  • 财政年份:
  • 资助金额:
    $ 19.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了